CYP3A5 *1 expressers exhibited statistically similar rates of neurotoxicity (33.3% vs. 20.1%; p = 0.33) and GVHD (50.0% vs. 49.5%; p = 0.97) as non-expressers. The gene discussed is CYP3A5; the disease is graft versus host disease.